News | May 25, 2026
Anupam Rasayan to acquire 43.3%–48.2% equity stake in Bliss GVS Pharma
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
Veteran consumer health and FMCG strategist to lead preventive wellness and nutrition portfolio expansion through innovation and modern trade channels
Expands Davaindia network to 2,579 stores
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
With standout ADC and t-cell engager response data across hard-to-treat cancers
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
The approval was granted by Agenzia Italiana del Farmaco
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Subscribe To Our Newsletter & Stay Updated
